Sanofi signed a discovery and licensing agreement with Earendil Labs to use Earendil’s AI‑driven platform to discover bispecific antibodies for autoimmune and inflammatory diseases. The deal carries up to $2.56 billion in potential value, including $160 million in upfront and near‑term payments and tiered royalties on future sales. Earendil will provide its predictive protein modeling and high‑throughput validation capabilities while Sanofi will lead development and worldwide commercialization. Earendil’s CEO framed the collaboration as a step to scale AI‑enabled bispecific discovery across a broader target set, and Sanofi positioned the pact as part of a strategic push into next‑generation biologics.